Compare Stocks: PRAN, VTVT, RFL, and AARD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.38	$6.33	$3.35 ▼ $17.94	$117.71M	3.74	132,160 shs	257,808 shs
PRAN Alterity Therapeutics	$3.90 +3.7%	$1.41	$1.09 ▼ $2.91	$34.70M	1.05	130,956 shs	13,103 shs
RFL Rafael	$2.60 +1.6%	$2.31	$1.12 ▼ $3.96	$135.20M	0.4	113,502 shs	138,485 shs
VTVT vTv Therapeutics	$33.35	$33.02	$18.00 ▼ $44.00	$131.40M	0.29	60,657 shs	12,065 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	-7.08%	-31.90%	+49.86%	-37.44%
PRAN Alterity Therapeutics	0.00%	0.00%	0.00%	0.00%	-23.09%
RFL Rafael	0.00%	+3.17%	+25.24%	+60.30%	+79.31%
VTVT vTv Therapeutics	0.00%	+3.06%	-5.71%	+4.02%	+82.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.38	$6.33	$3.35 ▼ $17.94	$117.71M	3.74	132,160 shs	257,808 shs
PRAN Alterity Therapeutics	$3.90 +3.7%	$1.41	$1.09 ▼ $2.91	$34.70M	1.05	130,956 shs	13,103 shs
RFL Rafael	$2.60 +1.6%	$2.31	$1.12 ▼ $3.96	$135.20M	0.4	113,502 shs	138,485 shs
VTVT vTv Therapeutics	$33.35	$33.02	$18.00 ▼ $44.00	$131.40M	0.29	60,657 shs	12,065 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	-7.08%	-31.90%	+49.86%	-37.44%
PRAN Alterity Therapeutics	0.00%	0.00%	0.00%	0.00%	-23.09%
RFL Rafael	0.00%	+3.17%	+25.24%	+60.30%	+79.31%
VTVT vTv Therapeutics	0.00%	+3.06%	-5.71%	+4.02%	+82.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	2.42	Hold	$15.33	185.01% Upside
PRAN Alterity Therapeutics	0.00	N/A	N/A	N/A
RFL Rafael	1.00	Sell	N/A	N/A
VTVT vTv Therapeutics	2.67	Moderate Buy	$55.83	67.42% Upside

Current Analyst Ratings Breakdown

Latest PRAN, VTVT, RFL, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	VTVT vTv Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/25/2026	RFL Rafael	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/11/2026	VTVT vTv Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
8/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/6/2026	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $42.00
7/20/2026	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$6.00
7/16/2026	VTVT vTv Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$49.00 ➝ $57.00
7/2/2026	AARD Aardvark Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/30/2026	VTVT vTv Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$67.00
6/11/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$4.90 per share	N/A
PRAN Alterity Therapeutics	$150K	231.35	N/A	N/A	$1.40 per share	2.79
RFL Rafael	$920K	146.96	N/A	N/A	$1.91 per share	1.36
VTVT vTv Therapeutics	$1.02M	128.82	N/A	N/A	$16.36 per share	2.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$57.59M	-$3.21	N/A	N/A	N/A	N/A	-71.54%	-64.94%	N/A
PRAN Alterity Therapeutics	-$6.40M	-$0.70	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RFL Rafael	-$30.52M	-$0.68	N/A	N/A	N/A	-3,321.74%	-41.27%	-35.32%	10/28/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$1.06	N/A	N/A	N/A	N/A	-6.27%	-5.06%	11/5/2026 (Estimated)

Latest PRAN, VTVT, RFL, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	AARD Aardvark Therapeutics	-$0.87	-$0.66	+$0.21	-$0.66	N/A	N/A
8/6/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	-$1.05	-$0.08	-$1.05	$0.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAN Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
RFL Rafael	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	12.63	12.63
PRAN Alterity Therapeutics	N/A	4.37	N/A
RFL Rafael	N/A	3.16	3.14
VTVT vTv Therapeutics	N/A	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
PRAN Alterity Therapeutics	3.63%
RFL Rafael	11.30%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	17.80%
PRAN Alterity Therapeutics	38.80%
RFL Rafael	32.90%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.88 million	17.99 million	N/A
PRAN Alterity Therapeutics	14	8.90 million	N/A	Not Optionable
RFL Rafael	20	52.00 million	34.89 million	Optionable
VTVT vTv Therapeutics	9	3.94 million	3.70 million	Not Optionable

PRAN, VTVT, RFL, and AARD Headlines

Recent News About These Companies

Lifesci Capital Upgrades vTv Therapeutics (NASDAQ:VTVT) to Strong-Buy

September 4 at 7:05 AM | marketbeat.com

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

September 3, 2026 | theglobeandmail.com

vTv Therapeutics to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below 50-Day Moving Average - Should You Sell?

September 2, 2026 | marketbeat.com

vTv Therapeutics Inc. Cl A

August 30, 2026 | barrons.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 19, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts

August 18, 2026 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for vTv Therapeutics

August 10, 2026 | marketbeat.com

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026 | markets.businessinsider.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 28, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next

May 17, 2026 | finance.yahoo.com

Why vTv Therapeutics Inc.’s (VTVT) Stock Is Down 8.13%

May 16, 2026 | aaii.comA

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

May 15, 2026 | zacks.com

vTv Therapeutics Expands At-The-Market Share Program Capacity

May 13, 2026 | tipranks.com

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 8, 2026 | globenewswire.com

vTv Therapeutics to Participate in Upcoming May Investor Conferences

May 7, 2026 | globenewswire.com

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?

April 20, 2026 | zacks.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAN, VTVT, RFL, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$5.38 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Alterity Therapeutics NASDAQ:PRAN

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Rafael NYSE:RFL

$2.60 +0.04 (+1.56%)

As of 09/4/2026 03:56 PM Eastern

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

vTv Therapeutics NASDAQ:VTVT

$33.35 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRAN, VTVT, RFL, and AARD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRAN, VTVT, RFL, and AARD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRAN, VTVT, RFL, and AARD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAN, VTVT, RFL, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Alterity Therapeutics NASDAQ:PRAN

Rafael NYSE:RFL

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRAN, VTVT, RFL, and AARD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRAN, VTVT, RFL, and AARD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRAN, VTVT, RFL, and AARD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAN, VTVT, RFL, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Alterity Therapeutics NASDAQ:PRAN

Rafael NYSE:RFL

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools